The molecular bases for species barriers to lentiviral replication are
not well understood, but are of interest for explaining lentiviral pa
thogenesis, devising therapeutic strategies, and adapting lentiviruses
to gene therapy. HIV-l-based lentiviral vectors efficiently transduce
nondividing cells', but present complex safety concerns(2). Nonprimat
e (ungulate or feline) lentiviruses might provide safer alternatives,
but these viruses display highly restricted tropisms, and their potent
ial for adaptation as replication-defective vectors capable of transdu
cing human cells is unknown. Feline immunodeficiency virus (FIV) does
not infect humans or other non-Felidae despite prevalent natural expos
ure. Although long terminal repeat (LTR)-directed FIV expression was f
ound to be negligible in human cells, promoter substitution enabled an
env-deleted, three-plasmid, human cell-FIV lentiviral vector system t
o express high levels of FIV proteins and FIV vectors in human cells,
thus bypassing the hazards of feline vector producer cells. Pseudotype
d FIV vectors efficiently transduced dividing, growth-arrested, and po
stmitotic human targets. The experiments delineate mechanisms involved
in species-restricted replication of this lentivirus and show that hu
man cells support both productive- and infective-phase mechanisms of t
he FIV life cycle needed for efficient lentiviral vector transduction.
Nonprimate lentiviral vectors may offer safety advantages, and FIV ve
ctors provide unique experimental opportunities.